Phase II open-label study of recombinant circularly permuted TRAIL as a single-agent treatment for relapsed or refractory multiple myeloma

Table 3 Incidences of treatment-related adverse events^a after single-agent CPT treatment in 27 patients with RRMM

Adverse event	All grades^b	Grade 3/4^c
Overall adverse events	24 (88.9)	10 (37.0)
Fever	13 (48.1)	0 (0.0)
AST elevation	13 (48.1)	5 (18.5)
ALT elevation	12 (44.4)	2 (7.4)
Leukopenia	7 (25.9)	3 (11.1)
Rash	4 (14.8)	0 (0.0)
Neutropenia	4 (14.8)	3 (11.1)
Thrombocytopenia	3 (11.1)	2 (7.4)
Blood bilirubin elevation	2 (7.4)	1 (3.7)
Creatinine elevation	2 (7.4)	0 (0.0)
Upper respiratory infection	2 (7.4)	0 (0.0)
Uric acid elevation	1 (3.7)^d	1 (3.7)

Only those toxicities deemed possibly, probably, or definitely related to the treatment are included in the table. Note: a patient may have had more than one adverse event
AST aspartate aminotransferase, ALT alanine aminotransferase
^aAdverse events were assessed according to the Common Toxicity Criteria for Adverse Events. Data are presented as number of patients followed by percentage in the parentheses
^bAdverse event reported in at least 5% of the treated patients
^cAll patients with grade 3 or 4 adverse events
^dAlthough uric acid elevation occurred in only 1 patient (<5%), this adverse event was listed because it was grade 3

ISSN: 2523-3548